

## Anti-Human CD279 (PD1) Antibody

<b>Catalog Number:</b>	101401, 101402
<b>Size:</b>	100 ug, 500 ug
<b>Target Name:</b>	CD279, PD1, PD-1
<b>Regulatory Status:</b>	RUO

### PRODUCT DETAILS

---

<b>Clone:</b>	279AM1
<b>Application:</b>	Flow Cytometry
<b>Reactivity:</b>	Human
<b>Format:</b>	Purified
<b>Isotype:</b>	Mouse IgG1
<b>Antibody Type:</b>	Monoclonal
<b>Formulation:</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide
<b>Protein Concentration:</b>	0.5 mg/mL
<b>Storage&amp;Handling:</b>	The antibody solution should be stored between 2°C and 8°C
<b>Recommended Usage:</b>	For flow cytometric staining, it is recommended to use less than 0.2 ug of this reagent per 0.5-1.0 million cells in a 100 µL volume. Optimal reagent performance should be determined by titration for each specific application.
<b>Isotype Control:</b>	301401
<b>RRID:</b>	AB_3738610

### BACKGROUND INFORMATION

---

CD279, also known as Programmed Cell Death Protein 1 (PD-1), is a crucial immune checkpoint receptor that regulates T cell activation and prevents autoimmunity. This transmembrane protein plays a pivotal role in maintaining immune homeostasis by delivering inhibitory signals that dampen excessive immune responses.

PD-1 is a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily. It contains an extracellular immunoglobulin variable (IgV)-like domain, a transmembrane region, and an intracellular tail with two tyrosine-based signaling motifs: an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoreceptor tyrosine-based switch motif (ITSM). When engaged, these motifs recruit phosphatases that inhibit T-cell receptor signaling, effectively suppressing T-cell activation, proliferation, and cytokine production.


PD-1 interacts with two primary ligands: PD-L1 (B7-H1/CD274) and PD-L2 (B7-DC/CD273). PD-L1 is widely expressed on various cell types, including tumor cells, antigen-presenting cells, and non-hematopoietic tissues, while PD-L2 expression is more restricted to antigen-presenting cells. These ligand-receptor interactions serve as critical brakes on immune responses. In cancer, tumor cells exploit the PD-1/PD-L1 pathway to evade immune surveillance. By upregulating PD-L1 expression, tumors effectively "turn off"

infiltrating T-cells, preventing effective anti-tumor immunity. This mechanism contributes to tumor progression and immune escape across multiple cancer types.

The discovery of PD-1's role in cancer has revolutionized oncology through immune checkpoint inhibitors. Monoclonal antibodies targeting PD-1 (pembrolizumab, nivolumab) or PD-L1 (atezolizumab, durvalumab) block this inhibitory pathway, reinvigorating anti-tumor T-cell responses. These therapies have demonstrated remarkable success in treating melanoma, non-small cell lung cancer, renal cell carcinoma, and numerous other malignancies, fundamentally transforming cancer treatment paradigms and offering durable responses in previously untreatable cancers.

## PRODUCT DATA

---



Human peripheral blood lymphocytes stimulated with Anti-Human CD3/CD28 for three days were stained with purified anti-Human CD279 (PD-1) clone 279AM1 (color-filled histogram), followed by PE Anti-Mouse IgG.

This product is supplied subject to the terms and conditions at [www.innocyto.com/web/terms.php](http://www.innocyto.com/web/terms.php) and may only be used as provided in the stated terms. Products are for Research Use Only.